Way, way, way oversold. Someone is going to come in and scoop them up for $12-14/share, just like Hologic did. It's been the plan all along for Kevin.
Likely a Tetraphase buyout will follow.
If you use the mobile site you can view Abstracts with Data and Results for all the Tetraphase Poster sessions. Let's just say the results Eravacycline are impressive. :-)
Against Acinetobacter baumannii, including carbapenem-resistant strains, and Stenotrophomonas maltophilia Eravacycline was 2-4 times more potent than Tigecycline.
Against Gram-negative organisms, including drug-resistant phenotypes, isolated from respiratory sources in Europe was 4 time more potent than Tigecycline.
After reviewing the MIC data I bought more TTPH shares. Good luck.
Great conference this weekend in Amsterdam.